Resolution: standard / high
Figure 5.
TaqMan® PCR validation in training cohort and FFPE cohort. The relative quantitation from TaqMan® in recurrent vs primary tumours are plotted for both cohorts.
Laios et al. Molecular Cancer 2008 7:35 doi:10.1186/1476-4598-7-35
Download authors' original image